Resources Repository
-
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Mathematical Models | Decision Analysis | State-Transition | Costing Methods | Priority Setting/Ethics | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health/Medicine | Latin America & Caribbean -
ReviewPublication 2023How Values Are Discussed, Reflected Upon, and Acted on by Patients and Family Caregivers in the Context of Heart Failure: Scoping Review
The study examines how values influence decision-making and coping among heart failure (HF) patients and …
The study examines how values influence decision-making and coping among heart failure (HF) patients and their family caregivers (FCGs). Through a scoping review of 16 empirical studies, patient values were found to influence self-care behaviors and left ventricular assist device (LVAD) implantation decisions, with variations in prioritization over time and contexts. Conflicts between prioritized values and recommended self-care activities led to modifications in behavior. Patient survival emerged as a top value during cardiac device decisions.…
Evidence Synthesis | Preferences/Values | Decision Psychology | Chronic Disease/Risk | Health/Medicine -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Evidence Synthesis | Decision Analysis | Costing Methods | Health Outcomes | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine | Global | Graduate | Doctoral | Professional -
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
Mathematical Models | Decision Analysis | State-Transition | Microsimulation | Dynamic Simulation | Chronic Disease/Risk | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Government/Law | Health/Medicine | North America -
ReviewPublication 2011Simulation Models of Obesity: A Review of the Literature
Simulation models combine information from a variety of sources to provide a useful tool for …
Simulation models combine information from a variety of sources to provide a useful tool for examining how the effects of obesity unfold over time and impact population health. They can aid in the understanding of the complex interaction of the drivers of diet and activity and their relation to health outcomes. This paper provided an overview of different types of simulation models used to evaluate the potential impact of policies to address the obesity epidemic.…
Mathematical Models | Decision Analysis | State-Transition | Microsimulation | Calibration/Validation | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Economics/Finance | Food/Agriculture | Health/Medicine -
ReportPublication 2023Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing …
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing the growing significance of both qualitative and quantitative methods for studying these preferences. The report synthesizes current best practices to enhance the utility and impact of patient-preference studies. The methods involved reviewing existing literature and practices to construct the ISPOR Roadmap for Patient Preferences in Decision Making. This roadmap encourages collaboration among researchers, decision-makers, patients, patient groups, and other stakeholders.…
Evidence Synthesis | Preferences/Values | Health Outcomes | Health/Medicine -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Evidence Synthesis | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Europe -
ReviewPublication 2023Economic & Humanistic Burden of Osteoarthritis: Systematic Review of Large Sample Studies
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported …
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported by large sample studies since 2016. Medline (via Ovid) and Embase were searched using an updated strategy based on a previous review. Studies with a sample size ≥1000 that measured direct or indirect costs or health-related quality of life (HRQL) of OA were included. Pairs of reviewers independently screened studies, and an arbitrator resolved discrepancies. The Kappa value for agreement…
Evidence Synthesis | Preferences/Values | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Evidence Synthesis | Preferences/Values | Technology Assessment | Policy/Regulation | Health/Medicine